Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.3652W HIGH $13.90
Volume
1.47 M
Value Traded
16.52 M
Short % Float
17.14%
-0.19%Week
-8.38%1 Month
-2.84%3 Month
+21.56%6 Month
-52.77%5 Year
-13.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
942.98 M
EPS (TTM)
-3.34
P/E Ratio
-
Ent. Value
433.75 M
Total Shares
88.96 M
Float Shares
86.49 M
Insiders
2.78%
Institutions
100.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KURA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kura Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kura Oncology, Inc.
807Total events
30Upcoming
111Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationKO-7246Presentation
KO-7246 findings presented at 62nd EASD Annual Meeting
Type 1 and Type 2 diabetessource ↗
▲Preclinical PoCKO-7246Preclinical
KO-7246 preclinical data in Type 1 and Type 2 diabetes models presented at EASD
Type 1 and Type 2 diabetessource ↗
▲Partnership / LicenseCorporate
Kura Oncology launches Caspian Therapeutics, contributing KO-7246 and related IP; retains approximately half ownership
▲Equity OfferingCorporate
Caspian Therapeutics completes $50 million financing led by BVF Partners
●Management ChangeCorporate
Robert Spencer, Ph.D. appointed President and Chief Operating Officer of Caspian
●Enrollment UpdateZiftomenibApprovedTrial
Enrollment ongoing in KOMET-007 cohort with quizartinib
newly diagnosed FLT3/NPM1 co-mutated AMLsource ↗
●Enrollment UpdateDarlifarnibTrial
Enrollment continues in FIT-001 Phase 1b dose expansion
cabozantinib-naïve ccRCCsource ↗
●IND Enabling CompleteKO-7246Preclinical
Advance KO-7246 into IND-enabling studies
diabetes and cardiometabolic diseasesource ↗
▲Partnership / LicenseCorporate
Anticipated collaboration payments from Kyowa Kirin of $180 million
●Preclinical PoCPreclinical
Progress preclinical development of next-generation menin inhibitor for solid tumors
solid tumorssource ↗
●Oral PresentationPresentation
Present additional scientific data characterizing menin inhibitors in preclinical models of diabetes
diabetessource ↗
▲PublicationZiftomenibApprovedPresentation
Publication in Blood detailing discovery and preclinical characterization of ziftomenib
acute leukemiassource ↗
▲Oral PresentationDarlifarnibPresentation
Updated Phase 1a results presented at KCRS 2026
clear cell renal cell carcinomasource ↗
◆Enrollment UpdateDarlifarnibTrial
Enrolling patients in randomized Phase 1b portion
clear cell renal cell carcinomasource ↗
▲Trial InitiationDarlifarnibTrial
Randomized Phase 1b portion of FIT-001 underway
clear cell renal cell carcinomasource ↗
◆Enrollment UpdateDarlifarnibTrial
Enrolling patients in randomized Phase 1b dose-optimization portion of FIT-001
advanced ccRCCsource ↗
▲Product LaunchZiftomenibApprovedPost-Market
KOMZIFTI achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class
relapsed or refractory NPM1-mutated acute myeloid leukemiasource ↗
◆Oral PresentationZiftomenibApprovedPresentation
Oral presentation of updated frontline ziftomenib/7+3 combination data at EHA 2026
newly diagnosed NPM1-mutant or KMT2A-rearranged acute myeloid leukemiasource ↗
◆Poster PresentationZiftomenibApprovedPresentation
Poster presentation of exposure-response analysis of ziftomenib combinations at EHA 2026
newly diagnosed and relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemiasource ↗
▲Oral PresentationZiftomenibApprovedPresentation
Long-term results from KOMET-007 presented at EHA 2026 Congress
newly diagnosed NPM1-mutant or KMT2A-rearranged AMLsource ↗
▲Full ResultsZiftomenibApprovedClinical Data
Encouraging long-term results from KOMET-007: 12-month OS rate 94% in NPM1-m, 71% in KMT2A-r; CRc 96% and 90% respectively
newly diagnosed NPM1-mutant or KMT2A-rearranged AMLsource ↗
●Oral PresentationPresentation
Kura to host virtual investor event on darlifarnib data, platform strategy, and development plans
▲Topline ReadoutDarlifarnibClinical Data
Preliminary Phase 1a data from darlifarnib + adagrasib presented at ASCO 2026
KRAS G12C-mutated cancers (PDAC, NSCLC, CRC)source ↗
▲Preclinical PoCDarlifarnibPreclinical
Preclinical data demonstrate darlifarnib inhibits RHEB farnesylation and sustains mTORC1 suppression, enhancing anti-tumor activity across RAS inhibitor classes
KRAS-mutant cancerssource ↗
▲Full ResultsZiftomenibApprovedClinical Data
Publication in Blood of updated results from KOMET-007 Phase 1a/1b trial evaluating ziftomenib in combination with venetoclax and azacitidine in R/R NPM1-m AML
relapsed/refractory NPM1-mutated acute myeloid leukemiasource ↗
▲FDA ApprovalZiftomenibApprovedFDA Decision
FDA approval of KOMZIFTI (ziftomenib) as monotherapy for adult patients with R/R NPM1-mutated AML
relapsed or refractory AML with a susceptible NPM1 mutationsource ↗
●Trial InitiationZiftomenibApprovedTrial
Ongoing pivotal KOMET-017 Phase 3 trials in newly diagnosed NPM1-m and KMT2A-r AML
newly diagnosed NPM1-mutated and KMT2A-rearranged AMLsource ↗
▲Oral PresentationZiftomenibApprovedPresentation
Long-term KOMET-007 data presented at EHA 2026
newly diagnosed NPM1-m or KMT2A-r AMLsource ↗
▲PublicationZiftomenibApprovedPresentation
Updated KOMET-007 results published in Blood
relapsed/refractory NPM1-m AMLsource ↗
▲Oral PresentationDarlifarnibPresentation
First-in-human Phase 1 FIT-001 data presented at ASCO 2026
KRAS G12C-mutated solid tumorssource ↗
◆Oral PresentationDarlifarnibPresentation
ASCO 2026 presentation of darlifarnib + adagrasib data
KRAS G12C-mutated solid tumorssource ↗
◆Oral PresentationPresentation
Kura Oncology to present at TD Cowen 7th Annual Oncology Innovation Summit
▲Topline ReadoutDarlifarnibClinical Data
First-in-human data from FIT-001 trial of darlifarnib + adagrasib
KRAS G12C-mutated solid tumorssource ↗
◆Oral PresentationPresentation
Kura Oncology to participate in Bank of America Securities Healthcare Conference fireside chat
●Oral PresentationPresentation
Management webcast and conference call to discuss Q1 2026 results
●Poster PresentationZiftomenibApprovedPresentation
Online publication of KOMET-017 trial design at EHA 2026
newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemiasource ↗
◆Oral PresentationDarlifarnibPresentation
Updated data from FIT-001 trial of darlifarnib plus cabozantinib in ccRCC patients after prior cabozantinib at IKCS Europe 2026
clear cell renal cell carcinomasource ↗
▲Product LaunchZiftomenibApprovedPost-Market
First full quarter of commercial availability for KOMZIFTI
relapsed/refractory NPM1-mutant AMLsource ↗
Past FDA Catalysts and PDUFA Decisions
How KURA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-29 | KO-7246 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$248M
Pipeline Value
$183M
Commercial Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 26%
Micro Cap(rank 172 of 660)
Percentile Rank
Kura Oncology, Inc. carries a moderate pipeline score (46/100), with $770M risk-adjusted pipeline value, led by Tipifarnib in Leukemia, Myelomonocytic, Chronic (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $77.2M x 2.4 = $183M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| KOMZIFTI | $17M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tipifarnib Small moleculeCompletedNCT02464228 | Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 2 | COMPLETED | 65 | Mar 31, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every KURA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| darlifarnib plus cabozantinib | advanced clear cell renal cell carcinoma (ccRCC) | Phase 1a | 2026-07-27 | objective response rate: up to 50%; median progression free survival: 13 months; response rate range: 33% to 50%; patients: N=34Read More | Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Powl Brian T.Officer (Chief Commercial Officer) | Sell | -15,430 136,819 held | $10.75 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KURA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 2.4 % (9.1 %) | 92.65 M | 8.45 M |
KURA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KURA ranks across every disease it competes in
Competitive Position is a premium feature
See how KURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKURA News
KURA▲ +0.9%today
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Caspian Therapeutics and Kura Oncology will host an investor webcast on October 13, 2026, to discuss the formation of Caspian and present preclinical data on KO-7246, a menin inhibitor for diabetes. The event will highlight the potential of KO-7246 in restoring insulin production and its development strategy in cardiometabolic diseases.
Read more →KURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology announced the granting of inducement stock options to nine new employees as part of its 2023 Inducement Option Plan. Each option allows the purchase of shares at $10.65, the stock's closing price on the grant date. The options will vest over four years, promoting employee retention and aligning with Nasdaq regulations.
Read more →KURACaspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
Caspian Therapeutics has announced promising preclinical data for KO-7246, a menin inhibitor aimed at treating Type 1 and Type 2 diabetes. The compound has demonstrated the ability to regenerate functional β-cell mass and maintain glycemic control in animal models. KO-7246's unique mechanism may enhance existing diabetes treatments, positioning it as a potential best-in-class therapy.
Read more →KURAKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology has launched Caspian Therapeutics, focusing on advancing KO-7246, a menin inhibitor aimed at treating diabetes. The company secured $50 million in financing to support the drug's development through initial clinical proof of concept. Preclinical studies indicate that KO-7246 may enhance pancreatic beta cell function and insulin production, presenting a novel approach to diabetes treatment.
Read more →KURA▼ -5.5%on this newsshared move
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology has appointed Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Fulk, with over 20 years of experience in biopharmaceutical finance, will join the senior leadership team and report to CEO Troy Wilson. Her expertise is expected to enhance Kura's capital allocation and execution strategies as the company advances its oncology franchises.
Read more →KURAKura Oncology to Participate in Three Investor Conferences in September
Kura Oncology will participate in three investor conferences in September 2026, showcasing its commitment to engaging with the investment community. The conferences include the Wells Fargo Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley Global Healthcare Conference. Live audio webcasts will be available on Kura's website, with archived replays following each event.
Read more →KURAKura Oncology Reports Second Quarter 2026 Financial Results
Kura Oncology reported strong second quarter 2026 results, with KOMZIFTI generating $9.1 million in revenue and achieving a majority share of new patient starts in the menin inhibitor class. The company presented promising long-term data for ziftomenib, indicating its potential to transform AML treatment. Despite a net loss of $68.3 million, Kura maintains a robust cash position to support ongoing and future clinical programs.
Read more →KURAKura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Kura Oncology announced the publication of research in 'Blood' detailing ziftomenib's discovery and preclinical activity. The findings highlight its differentiated binding profile and efficacy against specific mutations in acute leukemias. Ziftomenib, approved for relapsed or refractory NPM1-mutated AML, shows promise as a foundational therapy in combination with existing treatments.
Read more →KURAKura Oncology to Report Second Quarter Financial Results
Kura Oncology will report its second quarter 2026 financial results on August 12, 2026. A conference call and webcast will follow to discuss the results and provide updates. The company focuses on precision medicines for cancer, with an FDA-approved drug targeting NPM1-mutated acute myeloid leukemia.
Read more →KURAKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology reported promising results from its Phase 1a trial of darlifarnib plus cabozantinib in cabozantinib-naïve patients with advanced clear cell renal cell carcinoma (ccRCC). The trial showed response rates of up to 50% and a median progression-free survival of 13 months. The combination therapy was well tolerated, supporting its further development in clinical settings. A randomized Phase 1b study is currently underway to optimize dosing for future trials.
Read more →KURAKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Kura Oncology announced that updated Phase 1a results for darlifarnib in combination with cabozantinib will be presented at the 2026 Kidney Cancer Research Summit. The data aims to demonstrate darlifarnib's potential to enhance VEGFR-targeted therapies in advanced renal cell carcinoma. Ongoing studies continue to evaluate its efficacy in combination with cabozantinib.
Read more →KURAKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced promising long-term results from the KOMET-007 trial, which evaluated ziftomenib combined with the 7+3 chemotherapy regimen in newly diagnosed AML patients. The trial reported a 94% overall survival rate for NPM1-m AML patients and a 71% rate for KMT2A-r AML patients, with high remission rates and favorable tolerability. These findings support the ongoing Phase 3 KOMET-017 study.
Read more →KURAKura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board
Kura Oncology, Inc. has amended and restated its 2014 Equity Incentive Plan to enhance employee engagement and retention. This plan enables the granting of various awards including stock options and performance awards while allowing the Board to make necessary adjustments. The amendments also highlight Kura's intent to keep pace with the evolving needs of its workforce and market conditions. Stockholder approvals are recurring elements in the plan's amendment timeline, indicating a structured governance approach.
Read more →KURAKura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology has presented promising preliminary Phase 1a data for darlifarnib in combination with adagrasib, showing significant response rates in various KRAS-mutant cancers. The company plans to initiate a platform study to evaluate darlifarnib across multiple therapies, starting with a combination in pancreatic cancer expected in early 2027. The findings reinforce darlifarnib's potential as a foundational treatment option in the evolving landscape of KRAS inhibitors.
Read more →KURAKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology and Kyowa Kirin announced promising results from the KOMET-007 trial, evaluating ziftomenib combined with venetoclax and azacitidine in patients with relapsed/refractory NPM1-mutated acute myeloid leukemia. The combination showed an 87% overall response rate in venetoclax-naïve patients and was well tolerated. The findings highlight the potential of this combination therapy in addressing unmet needs in AML treatment.
Read more →KURA▼ -7.5%on this news
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology reported promising results from the FIT-001 trial, showing that the combination of darlifarnib and adagrasib achieved significant tumor shrinkage in 77% of response-evaluable patients with KRAS G12C-mutated solid tumors. The objective response rates were notable, with 67% in pancreatic ductal adenocarcinoma, 50% in non-small cell lung cancer, and 29% in colorectal cancer. The findings suggest darlifarnib's potential as a precision therapy in overcoming resistance to existing treatments.
Read more →About Kura Oncology, Inc.
Headquarters4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next KURA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime